CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 63 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,344,160 | -41.9% | 61,574 | -15.4% | 0.00% | -50.0% |
| Q2 2023 | $2,313,454 | +71.0% | 72,773 | +31.2% | 0.00% | +100.0% |
| Q1 2023 | $1,352,888 | -22.6% | 55,469 | +0.0% | 0.00% | -50.0% |
| Q4 2022 | $1,748,956 | +23.6% | 55,452 | +10.8% | 0.00% | 0.0% |
| Q3 2022 | $1,415,000 | +10.3% | 50,036 | +3.2% | 0.00% | +100.0% |
| Q2 2022 | $1,283,000 | -0.6% | 48,503 | +31.5% | 0.00% | 0.0% |
| Q1 2022 | $1,291,000 | +24.5% | 36,881 | +15.4% | 0.00% | 0.0% |
| Q4 2021 | $1,037,000 | +27.9% | 31,961 | +16.2% | 0.00% | – |
| Q3 2021 | $811,000 | +107.4% | 27,497 | +80.2% | 0.00% | – |
| Q2 2021 | $391,000 | +119.7% | 15,262 | +17.9% | 0.00% | – |
| Q1 2021 | $178,000 | – | 12,947 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,912,345 | 41.46% |
| Perceptive Advisors | 6,511,727 | $205,379,869 | 5.77% |
| Finepoint Capital LP | 517,287 | $16,315 | 5.28% |
| Artal Group S.A. | 1,900,000 | $59,926 | 3.34% |
| Affinity Asset Advisors, LLC | 215,000 | $6,781,100 | 2.66% |
| Rock Springs Capital Management LP | 2,506,464 | $79,053,875 | 1.90% |
| Hood River Capital Management LLC | 923,638 | $29,131,543 | 1.06% |
| Logos Global Management LP | 260,000 | $8,200,400 | 0.96% |
| Frazier Life Sciences Management, L.P. | 393,000 | $12,395,220 | 0.77% |
| FEDERATED HERMES, INC. | 2,867,451 | $90,439,405 | 0.25% |